ArticleDrug delivery2026
Comparative safety profiles of antibody-drug conjugates: a real-world analysis of monotherapy and combination regimens in solid tumors.
Linjie Fan, Yuze Yin, Wei Zhuang, Danming He, Rui Wan, Boyang Sun, Hua Bai, Jie Wang
Abstract readComparative Study
In one paragraphArticle in Drug delivery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
Linjie FanDepartment of Medical Oncology, and National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, CAMS Key Laboratory of Translational Research on Lung Cancer, State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.ORCID 0009-0002-5571-3334 Yuze YinDepartment of Medical Oncology, and National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, CAMS Key Laboratory of Translational Research on Lung Cancer, State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.ORCID 0009-0009-5605-8045 Wei ZhuangDepartment of Medical Oncology, and National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, CAMS Key Laboratory of Translational Research on Lung Cancer, State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Danming HeDepartment of Medical Oncology, and National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, CAMS Key Laboratory of Translational Research on Lung Cancer, State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Rui WanDepartment of Medical Oncology, and National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, CAMS Key Laboratory of Translational Research on Lung Cancer, State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Boyang SunDepartment of Medical Oncology, and National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, CAMS Key Laboratory of Translational Research on Lung Cancer, State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Hua BaiDepartment of Medical Oncology, and National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, CAMS Key Laboratory of Translational Research on Lung Cancer, State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.ORCID 0000-0002-3179-8137 Jie WangDepartment of Medical Oncology, and National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, CAMS Key Laboratory of Translational Research on Lung Cancer, State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.ORCID 0000-0002-5602-0487 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
The expanding clinical use of Antibody-Drug Conjugates (ADCs) necessitates a clearer understanding of their real-world toxicity profiles across diverse clinical settings. This retrospective pharmacovigilance study analyzed 19,697 adverse event (AE) reports for seven approved ADCs from the FDA Adverse Event Reporting System (FAERS) database (Q1 2004 to Q1 2025). Using disproportionality analysis validated by multivariable logistic regression, we identified safety signals for both monotherapy and combination regimens. The analysis revealed that toxicity profiles are strongly driven by an ADC's molecular structure and treatment setting. Target-specific 'on-target, off-tumor' effects were prominent, linking Nectin cell adhesion molecule 4 (NECTIN-4) targeting to skin reactions, Trophoblast cell-surface antigen 2 (TROP2) to gastrointestinal toxicities, and both folate receptor
Indexed as
Antineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsImmunoconjugatesNeoplasmsAdverse Drug Reaction Reporting SystemsHumansPharmacovigilanceRetrospective StudiesUnited StatesAntineoplastic AgentsImmunoconjugatesAntibody-drug conjugatescombination therapyFAERSstructure-toxicity relationshiptoxicity profile
Identifiers
PMID42557654
PMCPMC13449428
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390